Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
|
|
- Jean Scott
- 6 years ago
- Views:
Transcription
1 Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical Center Program Director, Thoracic Surgery Co-Director, Thoracic Oncology Research Laboratory Director, Clinical Oncology, Duke Comprehensive Cancer Center
2 Disclosure Consultant Covidien Scanlan No conflicts related to this presentation
3 The Debate: SBRT/RFA vs Lobectomy in Clinical Stage I NSCLC Not a debate about the efficacy of SBRT/RFA in selected patients Not a debate about the role of thoracic surgeons in evaluating or using SBRT/RFA Not a debate regarding the superiority of lobectomy over lesser resection
4 Lobectomy for c-stage I NSCLC 1. Inaccurate staging: c-stage I p-stage I 2. Thoracoscopic lobectomy/segmentectomy achieves complete resection and nodal staging, with low complication rates 3. Without tissue, biologic staging and treatment strategies are less effective
5 Staging Lung Cancer 1. Clinical staging of lung cancer is inaccurate 5-year survival Clinical Stage I 57% Pathologic Stage I 67% A substantial fraction of patients with c-stage I NSCLC are not p-stage I NSCLC
6 CT: Induction Freidman Clinical Stage I by CT and PET
7 CT: Induction Freidman N3 at Mediastinoscopy
8 Mediastinal Staging with PET Study N Sensitivity Specificity Iowa (Ann Thorac Surg 2002;73:394) Duke University Medical Center (J Thorac Cardiovasc Surg 2003; 126: ) ACOSOG Z0050 (J Thorac Cardiovasc Surg 2003;126: ) % 82% % 77% % 84% % 81%
9 Mediastinal Staging with PET Study N Sensitivity Specificity Iowa (Ann Thorac Surg 2002;73:394) % 82% Duke University Medical Center (J Thorac Cardiovasc Surg 2003; 126: ) ACOSOG Z0050 (J Thorac Cardiovasc Surg 2003;126: ) % 77% 25% % 84% Under-staged % 81%
10 Serum CEA in Surgically Resected Clinical Stage I Patients With NSCLC Sawabata N et al Ann Thorac Surg 2002;74: N=297 IA % IB 79 27% IIA 6 2% IIB 12 4% IIIA 23 8% IIIB 13 4% IV 8 3%
11 Serum CEA in Surgically Resected Clinical Stage I Patients With NSCLC Sawabata N et al Ann Thorac Surg 2002;74: N=297 IA % IB 79 27% IIA 6 2% IIB 12 4% 20% IIIA 23 8% IIIB 13 4% Under-staged IV 8 3%
12 Risk Factors For Occult Mediastinal Metastases In Clinical Stage I NSCLC Lee PC et al. Ann Thorac Surg 2007;84: N=224 IA % IB 51 23% IIA 6 3% IIB 16 7% IIIA 12 5% IIIB 18 8% IV 3 1%
13 Risk Factors For Occult Mediastinal Metastases In Clinical Stage I NSCLC Lee PC et al. Ann Thorac Surg 2007;84: N=224 IA % IB 51 23% IIA 6 3% IIB 16 7% 24% IIIA 12 5% IIIB 18 8% Under-staged IV 3 1%
14 Clinical staging will underestimate extent of disease in 20-25% of patients Strategies that attempt local control without pathologic staging will be inadequate, especially disappointing in patients with curable N1 and N2 disease
15 2. The risks of surgery may be overestimated in patients that undergo thoracoscopic lobectomy, which should be feasible in nearly all patients with clinical stage I NSCLC that would be candidates for SBRT/RFA
16 Thoracoscopic Lobectomy is Associated with Fewer Postoperative Complications Villamizar N, et al. J Thorac Cardiovasc Surg 2009; 138: Western Thoracic Surgical Association 2008 Compared outcomes after lobectomy (n=1079) Thoracoscopic (n=697) vs Thoracotomy (n=382) Propensity analysis (n=284 each) matching preoperative variables and stage Analysis of postoperative complications
17 Propensity Matching: Greedy 5 to 1 Algorithm Demographics Fx Status Co-morbidity PFTS Other Age Zubrod score HTN FEV1 Stage Gender ASA CAD FVC Smoking BMI CHF DLCO Steroid Use DM Preop Chemo CVD Preop XRT CRI Elective Status Thoracotomy N=284 Thoracoscopy N=284
18 Outcomes: Propensity Matched Feature THOR (n=284) VATS (n=284) P No Complication, n (%) 144 (51%) 196 (69%) Atrial Fibrillation, n (%) 61 (21%) 37 (13%) 0.01 Atelectasis, n (%) 34 (12%) 15 (5%) Prolonged air leak, n (%) 55 (19%) 37 (13%) 0.05 Pneumonia, n (%) 27 (10%) 14 (5%) 0.05 Transfusion, n (%) 36 (13%) 11 (4%) 0.02 Renal Failure, n (%) 15 (5%) 4 (1.4%) 0.02 Death, n (%) 15 (5%) 8 (3%) 0.20 Chest tube duration (days) Length of stay (days)
19 Outcomes: Propensity Matched Feature THOR (n=284) VATS (n=284) P No Complication, n (%) 144 (51%) 196 (69%) Atrial Fibrillation, n (%) 61 (21%) 37 (13%) 0.01 Atelectasis, n (%) 34 (12%) 15 (5%) Prolonged air leak, n (%) 55 (19%) 37 (13%) 0.05 Pneumonia, n (%) 27 (10%) 14 (5%) 0.05 Transfusion, n (%) 36 (13%) 11 (4%) 0.02 Renal Failure, n (%) 15 (5%) 4 (1.4%) 0.02 Death, n (%) 15 (5%) 8 (3%) 0.20 Chest tube duration (days) Length of stay (days)
20 Thoracoscopic Lobectomy is Associated with Lower Morbidity than Open Lobectomy: A Propensity-Matched Analysis from the STS Database AATS 2009 J Thorac Cardiovasc Surg 2010: 139: Subroto Paul MD, Jeffrey L. Port MD, Shubin Sheng PhD, Paul C. Lee MD, David H. Harpole MD, Mark W. Onaitis MD, Brendon M. Stiles MD, Nasser K. Altorki MD, Thomas A. D Amico MD
21 STS-GTD ( ) 6365 Patients 6323 Patients Exclude Prior Thoracic Surgery (8) Missing Age or Gender Data (17) Other (17) Thoracotomy N=5042 Thoracoscopy N=1281
22 Propensity Matching: Greedy 5 to 1 Algorithm Demographics Fx Status Co-morbidity PFTS Other Age Zubrod score HTN FEV1 Stage Gender ASA CAD FVC Smoking BMI CHF DLCO Steroid Use DM Preop Chemo CVD Preop XRT CRI Elective Status Thoracotomy N=1281 Thoracoscopy N=1281
23 Postoperative Complication Thoracotomy (n=1281) Outcomes Thoracoscopy (n=1281) P Value* No complications 847 (65%) 945 (74%) <0.0001* All Cardiovascular 167 (13%) 106 (8%) * Atrial Arrhythmia 147 (12%) 93 (7%) * All Pulmonary 156 (12%) 97 (7%) * Reintubation 40 (3.1%) 18 (1.4%) * Postoperative Blood Transfusion 60 (4.7%) 31 (2.4%) *
24 Postoperative Complication Thoracotomy (n=1281) Outcomes Thoracoscopy (n=1281) P Value* No complications 847 (65%) 945 (74%) <0.0001* All Cardiovascular 167 (13%) 106 (8%) * Atrial Arrhythmia 147 (12%) 93 (7%) * All Pulmonary 156 (12%) 97 (7%) * Reintubation 40 (3.1%) 18 (1.4%) * Postoperative Blood Transfusion 60 (4.7%) 31 (2.4%) *
25 Postoperative Complication Thoracotomy (n=1281) Outcomes Thoracoscopy (n=1281) P Value* No complications 847 (65%) 945 (74%) <0.0001* All Cardiovascular 167 (13%) 106 (8%) * Atrial Arrhythmia 147 (12%) 93 (7%) * All Pulmonary 156 (12%) 97 (7%) * Reintubation 40 (3.1%) 18 (1.4%) * Postoperative Blood Transfusion 60 (4.7%) 31 (2.4%) *
26 Postoperative Complication Thoracotomy (n=1281) Outcomes Thoracoscopy (n=1281) P Value* No complications 847 (65%) 945 (74%) <0.0001* All Cardiovascular 167 (13%) 106 (8%) * Atrial Arrhythmia 147 (12%) 93 (7%) * All Pulmonary 156 (12%) 97 (7%) * Reintubation 40 (3.1%) 18 (1.4%) * Postoperative Blood Transfusion 60 (4.7%) 31 (2.4%) *
27 Thoracoscopic Lobectomy in High Risk Patients Under 70 Poor PFT n=207 (22%) Over 70 Poor PFT n=135 (14%) Over 70 Good PFT n=203 (22%) Low Risk n=398 (42%)
28 Thoracoscopic Lobectomy is Associated with Fewer Postoperative Complications in Patients >70 years Berry MF, et al Ann Thorac Surg 2009; 88: Thoracotomy VATS p No Cx 36% 61% A-fib 28% 18% 0.04 Respiratory Cx 12% 5% 0.03 Transfusion 16% 7% 0.01 Delirium 13% 5% 0.03
29 Thoracoscopic Lobectomy is Associated with Fewer Postoperative Complications in Patients >70 years Berry MF, et al Ann Thorac Surg 2009; 88: Thoracotomy VATS p No Cx 36% 61% A-fib 28% 18% 0.04 Respiratory Cx 12% 5% 0.03 Transfusion 16% 7% 0.01 Delirium 13% 5% 0.03
30 Thoracoscopic Lobectomy in High Risk Patients Under 70 Poor PFT n=207 (22%) Over 70 Poor PFT n=135 (14%) Over 70 Good PFT n=203 (22%) Low Risk n=398 (42%)
31 Pulmonary Function Tests Do Not Predict Complications after Thoracoscopic Lobectomy Berry MF et al. Ann Thorac Surg 2010; 89: Southern Thoracic Surgical Association 2009 Compared outcomes after lobectomy in patients with FEV1 or DLCO <60% predicted Propensity analysis, matching preoperative variables and stage Analysis of overall postoperative complications
32 Incidence of Pulmonary Complications by Approach DLCO FEV1
33 Thoracoscopic Lobectomy: Lower Morbidity Thoracoscopic Lobectomy Thoracotomy Relative Advantage No Cx (all) 72% 58% 25% No Cx (>70 yrs) 61% 36% 66% A-Fib (all) 9% 22% 130% A-Fib (>70 yrs) 18% 28% 60%
34 Pulmonary Segmentectomy Potential advantages of segmentectomy Preservation of pulmonary function (segmentdependent) compared to lobectomy Improved oncologic outcomes compared wedge resection
35 Pulmonary Segmentectomy Indications? Small T1 lesions Advanced COPD with lower lobe tumor Previous resections Central pulmonary metastases
36 Effect of tumor size on prognosis in patients with NSCLC: The role of segmentectomy Okada et al. J Thorac Cardiovasc Surg 2005;129: patients 5-year survival Stage I > 10 mm % 100% 11 to 20 mm % 92.6% 21 to 30 mm % 84.1% >30 mm % 76.4%, >30 mm lobectomy 81.3% >30 mm segment 62.9%
37 Effect of tumor size on prognosis in patients with NSCLC: The role of segmentectomy Okada et al. J Thorac Cardiovasc Surg 2005;129:87-93 Male, age, tumor size, stage adversely affected survival Authors conclude: < 20 mm Consider segmentectomy mm Further study > 30 mm Lobectomy
38 <20mm Disease-Free Survival <21-30mm Overall Survival >30mm
39 Radical sublobar resection for small-sized non small cell lung cancer: A multicenter study Okada et al. J Thorac Cardiovasc Surg 2006;132: Peripheral ct1n0m0 <2 cm (from 3 institutions) 5-year survival Sublobar (n = 305) 85.9% Lobar (n = 262) 83.4% Sublobar resection should be considered as an alternative for stage IA NSCLC 2 cm or less
40 Sublobar Resection for Patients With Peripheral Small Adenocarcinomas of the Lung: Surgical Outcome is Associated With Features on CT Nakayama et al Ann Thorac Surg 2007;84: patients with adenocarcinoma underwent sublobar resection of c-stage IA tumors measuring 2 cm or less Classified as "air-containing type" (46 patients) or "solid-density type" (17 patients) according to the tumor shadow disappearance rate on highresolution CT
41
42
43 Sublobar Resection for Patients With Peripheral Small Adenocarcinomas of the Lung: Surgical Outcome is Associated With Features on CT Nakayama et al Ann Thorac Surg 2007;84: Air-containing tumors 38 BAC and 8 non-bac No patient with air-containing tumors had recurrence (median f/u 70 months) 5-year survival Air-containing tumors 95% Solid-density tumors 57%
44 Pulmonary Segmentectomy: Thoracotomy Or Thoracoscopy Atkins BZ, et al. Ann Thorac Surg : sub-lobar anatomic resections ( ) Thoracotomy (OS) 29 patients Thoracoscopy (TS) 48 patients Retrospective review of prospectively-maintained thoracic surgery database
45 Thoracoscopic Segmentectomy: Outcomes OS (n=29) TS (n=48) Mortality 2 (7%) 0 Atrial arrhythmias 3 (10%) 7 (14%) Bleeding 1 (3%) 0 Prolonged air leak (>7d) 2 (7%) 5 (10%) Locoregional recurrences 1 (8%) 2 (8%) Distant recurrences 2 (17%) 0
46 Thoracoscopic Segmentectomy Compares Favorably With Thoracoscopic Lobectomy For Patients With Small Stage I Lung Cancer Shapiro M, et al. J Thorac Cardiovasc Surg 2009;137: Segmentectomy 31 pts and lobectomy 113 pts No difference in # of nodes/stations resected 5 (17%) recurrences after segmentectomy and 23 (20%) after lobectomy (P =.71); locoregional recurrence rates of 3.5% and 3.6%, respectively Pts after segmentectomy had lower FEV1 than after lobectomy (83% vs 92%, P =.04)
47 Lobectomy vs Limited Resection NCCN guidelines: Lobectomy is preferred over limited resection Segmentectomy preferred over wedge resection Segmentectomy: selected patients with tumors <2cm Tumor type (BAC) and location Age/Performance status Pulmonary function
48 CALGB : Phase III Trial of Lobectomy vs Sub-Lobar Resection for <2cm Peripheral NSCLC Pre-registration Surgery: Confirm pathologic dx of NSCLC and N0 status by frozen section of R4, 7, 10 or L5, 6, 10 R an d o m iz a ti o n Lobectomy Limited resection (segmentectomy or wedge)
49 3. Patients who undergo SBRT/RFA may not be eligible to be evaluated with biologic staging with state of the art techniques, and may not receive the benefits of adjuvant therapy
50 Metagene 5-year survival 90% 5-year survival <10%
51 Metagene
52 CALGB Resection: Stage I Randomize (2:1) Adjuvant Chemotherapy Observation Genomic Risk Analysis High Risk Low Risk High Risk Low Risk
53 Improving Outcomes with Stage I Lung Cancer Clinical staging is insufficient to define stage I disease; a significant fraction (20-25%) of c-stage I patients are undertreated by SRS/RFA The risks of surgical therapy in high-risk patients may be overestimated Biologic staging and treatment strategies are currently dependent on tissue acquisition
54 Caveats Surgical resection without appropriate management of hilar and mediastinal lymph nodes, both preoperatively and intraoperatively, is worse than SBRT/RFA In the future, it is possible that biologic techniques would identify which patients could benefit from SBRT/RFA
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationIndications for sublobar resection for localized NSCLC
Indications for sublobar resection for localized NSCLC David H Harpole Jr, MD Professor of Surgery Associate Professor in Pathology Vice Chief, Division of Surgical Services Duke University School of Medicine
More informationThoracoscopic Lobectomy: Technical Aspects in Years of Progress
Thoracoscopic Lobectomy: Technical Aspects in 2015 16 Years of Progress 8 th Masters of Minimally Invasive Thoracic Surgery Orlando September 25, 2015 Thomas A. D Amico MD Gary Hock Professor of Surgery
More informationROBOT SURGEY AND MINIMALLY INVASIVE TREATMENT FOR LUNG CANCER
ROBOT SURGEY AND MINIMALLY INVASIVE TREATMENT FOR LUNG CANCER Giulia Veronesi European Institute of Oncology Milan Lucerne, Samo 24 th - 25 th January, 2014 DIAGNOSTIC REVOLUTION FOR LUNG CANCER - Imaging
More informationVATS after induction therapy: Effective and Beneficial Tips on Strategy
VATS after induction therapy: Effective and Beneficial Tips on Strategy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J. Swanson, M.D. Professor of
More informationSagar Damle, MD University of Colorado Denver May 23, 2011
Sagar Damle, MD University of Colorado Denver May 23, 2011 We have debated many times. Here are the topics, and a recap of the last few Pre-operative nutrition Babu pro; Damle con Utility of ECMO Babu
More informationACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD
ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD 7-12-12 ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy
More informationHistory of Surgery for Lung Cancer
Welcome to Master Class for Oncologists Session 1: 7:30 AM - 8:15 AM San Francisco, CA October 23, 2009 Innovations in The Surgical Treatment of Lung Cancer Speaker: Scott J. Swanson, MD 2 Presenter Disclosure
More informationACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD
ACOSOG Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy Govindan, M.D. Carolyn Reed, MD
More informationCheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda
Original Article Comparison of perioperative and oncological outcomes between video-assisted segmentectomy and lobectomy for patients with clinical stage IA non-small cell lung cancer: a propensity score
More informationOBJECTIVES. Solitary Solid Spiculated Nodule. What would you do next? Case Based Discussion: State of the Art Management of Lung Nodules.
Organ Imaging : September 25 2015 OBJECTIVES Case Based Discussion: State of the Art Management of Lung Nodules Dr. Elsie T. Nguyen Dr. Kazuhiro Yasufuku 1. To review guidelines for follow up and management
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More informationThoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer
Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer Jin Gu Lee, MD, Byoung Chul Cho, MD, Mi Kyung Bae, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationVATS Segmentectomy. Duke Masters Course Sept 2015
VATS Segmentectomy Duke Masters Course Sept 2015 Scott J. Swanson, M.D. Director, Minimally Invasive Thoracic Surgery Brigham and Women s Hospital Chief Surgical Officer Dana Farber Cancer Institute Professor
More informationPost-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
More informationsurgical approach for resectable NSCLC
surgical approach for resectable NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France 1933 Graham EA, Singer JJ.
More informationLungebevarende resektioner ved lungecancer metode og resultater
Dept. of Cardiothoracic Surgery Lungebevarende resektioner ved lungecancer metode og resultater Henrik Jessen Hansen Dept. of Cardiothoracic Surgery RT 2152, The National University Hospital. Copenhagen,
More informationstate of the art standard of care for resectable NSCLC surgical approach for resectable NSCLC
state of the art standard of care for resectable NSCLC surgical approach for resectable NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationSTAGE I INOPERABLE NSCLC RADIOFREQUENCY ABLATION OR STEREOTACTIC BODY RADIOTHERAPY?
STAGE I INOPERABLE NSCLC RADIOFREQUENCY ABLATION OR STEREOTACTIC BODY RADIOTHERAPY? MICHAEL LANUTI, MD American Association of Thoracic Surgeons Minneapolis, MN 2013 STAGE I INOPERABLE NSCLC RADIOFREQUENCY
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationThoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
More informationLong-term respiratory function recovery in patients with stage I lung cancer receiving video-assisted thoracic surgery versus thoracotomy
Original Article Long-term respiratory function recovery in patients with stage I lung cancer receiving video-assisted thoracic surgery versus thoracotomy Tae Yun Park 1,2, Young Sik Park 2 1 Division
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationPreoperative Workup for Pulmonary Resection. Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016
Preoperative Workup for Pulmonary Resection Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016 Patient Presentation 50 yo male with 70 pack year smoking history Large R hilar lung
More informationIs Resection Superior to SBRT for Stage I Lesions. Traves Crabtree MD Professor of Surgery Southern Illinois University School of Medicine
Is Resection Superior to SBRT for Stage I Lesions Traves Crabtree MD Professor of Surgery Southern Illinois University School of Medicine I have nothing pertinent to disclose. Patterns of Recurrence for
More information11/21/ M with LUL Mass Case Presentation / Round Table Discussion. Multiple-choice question What stage is this tumor?
MS 62M with LUL Mass Case Presentation / Round Table Discussion Dr. Jasleen Kukreja and Johannes Kratz Department of Thoracic Surgery University of California, San Francisco 62M, presented to clinic 6/2009
More informationLONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert
More informationPneumonectomy After Induction Rx: Is it Safe?
Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationLung Cancer Clinical Guidelines: Surgery
Lung Cancer Clinical Guidelines: Surgery 1 Scope of guidelines All Trusts within Manchester Cancer are expected to follow this guideline. This guideline is relevant to: Adults (18 years and older) with
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationLung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany
17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 24-29 March, 2017 Berlin, Germany Lung cancer Surgery Sven Hillinger MD, Thoracic Surgery, University Hospital Zurich Case 1 59 y, female, 40 py, incidental
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More informationMastering Thoracoscopic Upper Lobectomy
Mastering Thoracoscopic Upper Lobectomy Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery, Duke University Medical
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationLung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationLymph Node Evaluation by Open or Video- Assisted Approaches in 11,500 Anatomic Lung Cancer Resections
RICHARD E. CLARK AWARD Lymph Node Evaluation by Open or Video- Assisted Approaches in 11,500 Anatomic Lung Cancer Resections Daniel J. Boffa, MD, Andrzej S. Kosinski, PhD, Subroto Paul, MD, John D. Mitchell,
More informationEarly and locally advanced non-small-cell lung cancer (NSCLC)
Early and locally advanced non-small-cell lung cancer (NSCLC) ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up P. E. Postmus, K. M. Kerr, M. Oudkerk, S. Senan, D. A. Waller, J.
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationShort-Term Results of Thoracoscopic Lobectomy and Segmentectomy for Lung Cancer in Koo Foundation Sun Yat-Sen Cancer Center
Original Article Short-Term Results of Thoracoscopic Lobectomy and Segmentectomy for Lung Cancer in Koo Foundation Sun Yat-Sen Cancer Center Bing-Yen Wang 1,2,3, Chia-Chuan Liu 1, Chih-Shiun Shih 1 1 Division
More informationThoracoscopic Lobectomy for locally advanced cancer. Todd L. Demmy
Thoracoscopic Lobectomy for locally advanced cancer Todd L. Demmy 5/13/15 No Disclosures What is Locally Advanced? >4 cm T3 or T4 Neoadjuvant chemotherapy Ann Surg Oncol (2011) 18:3732 3736 What is Locally
More informationOncologic Efficacy of Anatomic Segmentectomy in Stage IA Lung Cancer Patients With T1a Tumors
Oncologic Efficacy of Anatomic Segmentectomy in Stage IA Lung Cancer Patients With T1a Tumors James M. Donahue, MD, Christopher R. Morse, MD, Dennis A. Wigle, MD, PhD, Mark S. Allen, MD, Francis C. Nichols,
More informationDisclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
More informationVATS Metastasectomy. Inderpal (Netu) S. Sarkaria, MD, FACS
VATS Metastasectomy Inderpal (Netu) S. Sarkaria, MD, FACS Vice Chairman, Clinical Affairs Director, Robotic Thoracic Surgery Co-Director, Esophageal and Lung Surgery Institute Disclosures Speaking & Education:
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationOncology Clinical Service Line System-wide Consensus Guidelines: Treatment of Stage I Lung Cancer
Oncology Clinical Service Line System-wide Consensus Guidelines: Treatment of Stage I Lung Cancer These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes
More informationClinical Commissioning Policy Proposition: Robotic assisted lung resection for primary lung cancer
Clinical Commissioning Policy Proposition: Robotic assisted lung resection for primary lung cancer Reference: NHS England B10X03/01 Information Reader Box (IRB) to be inserted on inside front cover for
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationLarry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017
Larry Tan, MD Thoracic Surgery, HSC Community Cancer Care Educational Conference October 27, 2017 To describe patient referral & triage for the patient with suspected lung cancer To describe the initial
More informationVideo-assisted thoracoscopic surgery in lung cancer staging
Review Article on Thoracic Surgery Page 1 of 7 Video-assisted thoracoscopic surgery in lung cancer staging Frederico Krieger Martins, Guilherme Augusto Oliveira, Juliano Cé Coelho, Márcio Chmelnitsky Kruter,
More informationVideo-Mediastinoscopy Thoracoscopy (VATS)
Surgical techniques Video-Mediastinoscopy Thoracoscopy (VATS) Gunda Leschber Department of Thoracic Surgery ELK Berlin Chest Hospital, Berlin, Germany Teaching Hospital of Charité Universitätsmedizin Berlin
More informationPredictors of Disease-free Survival and Recurrence in Patients with Resected Bronchial Carcinoid Tumors
Original Thoracic 159 Predictors of Disease-free Survival and Recurrence in Patients with Resected Bronchial Carcinoid Tumors Paul C. Lee 1 Nonso C. Osakwe 1 Navnett Narula 2 Jeffrey L. Port 1 Subroto
More informationUnderstanding surgery
What does surgery for lung cancer involve? Surgery for lung cancer involves an operation, which aims to remove all the cancer from the lung. Who will carry out my operation? In the UK, we have cardio-thoracic
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationTHORACIK RICK. Lungs. Outline and objectives Richard A. Malthaner MD MSc FRCSC FACS
THORACIK RICK Outline and objectives Lungs Management of a solitary lung nodule Mediastinum Management of a mediastinal mass Pleura Management of a pleural fluid & pneumothorax Esophagus & Stomach Management
More informationVAMLA/TEMLA. Todd L. Demmy
VAMLA/TEMLA Todd L. Demmy Disclosures/ Questions Objectives - Staging Learn new lymphadenectomy (LA) results: Video-Assisted Mediastinal (VAMLA) Transcervical Extended Mediastinal (TEMLA) Compare with
More informationRobotic lobectomy has the greatest benefit in patients with marginal pulmonary function
Kneuertz et al. Journal of Cardiothoracic Surgery (2018) 13:56 https://doi.org/10.1186/s13019-018-0748-z RESEARCH ARTICLE Open Access Robotic lobectomy has the greatest benefit in patients with marginal
More informationSurgical management of lung cancer
Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More information8th Edition of the TNM Classification for Lung Cancer. Proposed by the IASLC
8th Edition of the TNM Classification for Lung Cancer Proposed by the IASLC Introduction Stage classification - provides consistency in nomenclature - improves understanding of anatomic extent of tumour
More informationQuality metrics for resection: Are they reasonable?
Quality metrics for resection: Are they reasonable? G. Alexander Patterson, MD Joseph C. Bancroft Professor of Surgery Division of Cardiothoracic Surgery Editor, Annals of Thoracic Surgery History of Outcomes
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationSublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer
Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko Higashiyama, MD, PhD, Tomio Nakayama, MD, PhD,
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationAccomplishes fundamental surgical tenets of R0 resection with systematic nodal staging for NSCLC Equivalent survival for Stage 1A disease
Segmentectomy Made Simple Matthew J. Schuchert and Rodney J. Landreneau Department of Cardiothoracic Surgery University of Pittsburgh Medical Center Financial Disclosures none Why Consider Anatomic Segmentectomy?
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationLobectomy Versus Sublobar Resection for Small (2 cm or Less) Non Small Cell Lung Cancers
Lobectomy Versus Resection for Small (2 cm or Less) Non Small Cell Lung Cancers Andrea S. Wolf, MD, William G. Richards, PhD, Michael T. Jaklitsch, MD, Ritu Gill, MD, Lucian R. Chirieac, MD, Yolonda L.
More informationDr. Thomas D Amico serves as a consultant for Scanlan. The other authors have no conflicts of interest to report.
Adjuvant Radiation is Not Associated with Improved Survival in Patients with Positive Margins Following Lobectomy for Stage I & II Non-Small Cell Lung Cancer Brian C Gulack, MD; Jeffrey Chi-Fu Yang, MD;
More informationClinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis
Original Article Clinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis Seok Joo 1, Dong Kwan Kim 2, Hee Je Sim
More informationMultifocal Lung Cancer
Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department
More informationVariability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival
Variability in Defining T1N0 Non-Small Cell Lung Cancer Impacts Locoregional Failure and Survival Mert Saynak, MD, Jessica Hubbs, MS, Jiho Nam, MD, Lawrence B. Marks, MD, Richard H. Feins, MD, Benjamin
More informationRobotic-assisted thoracoscopic sleeve lobectomy for locally advanced lung cancer
Original Article Robotic-assisted thoracoscopic sleeve lobectomy for locally advanced lung cancer Mong-Wei Lin, Shuenn-Wen Kuo, Shun-Mao Yang, Jang-Ming Lee Department of Surgery, National Taiwan University
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationMinimally Invasive Esophagectomy- Valuable. Jayer Chung, MD University of Colorado Health Sciences Center December 11, 2006
Minimally Invasive Esophagectomy- Valuable Jayer Chung, MD University of Colorado Health Sciences Center December 11, 2006 Overview Esophageal carcinoma What is minimally invasive esophagectomy (MIE)?
More informationFacing Surgery for Lung Cancer? Learn about minimally invasive da Vinci Surgery
Facing Surgery for Lung Cancer? Learn about minimally invasive da Vinci Surgery Treatments & Surgery Options: The treatment and surgical options for the most common lung cancer, non-small cell lung cancer,
More informationUniportal video-assisted thoracoscopic surgery segmentectomy
Case Report on Thoracic Surgery Page 1 of 5 Uniportal video-assisted thoracoscopic surgery segmentectomy John K. C. Tam 1,2 1 Division of Thoracic Surgery, National University Heart Centre, Singapore;
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationThe 7th Edition of TNM in Lung Cancer.
10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic
More informationDetermining the Optimal Surgical Approach to Esophageal Cancer
Determining the Optimal Surgical Approach to Esophageal Cancer Amit Bhargava, MD Attending Thoracic Surgeon Department of Cardiovascular and Thoracic Surgery Open Esophagectomy versus Minimally Invasive
More informationComplete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
More informationOncology Clinical Service Line System-wide Consensus Guidelines: Treatment of Stage I Lung Cancer
Oncology Clinical Service Line System-wide Consensus Guidelines: Treatment of Stage I Lung Cancer These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes
More informationSURGICAL TECHNIQUE. Radical treatment for left upper-lobe cancer via complete VATS. Jun Liu, Fei Cui, Shu-Ben Li. Introduction
SURGICAL TECHNIQUE Radical treatment for left upper-lobe cancer via complete VATS Jun Liu, Fei Cui, Shu-Ben Li The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China ABSTRACT KEYWORDS
More informationMINIMALLY INVASIVE ESOPHAGECTOMY FOR CANCER: where do we stand?
MINIMALLY INVASIVE ESOPHAGECTOMY FOR CANCER: where do we stand? Ph Nafteux, MD Copenhagen, Nov 3rd 2011 Department of Thoracic Surgery, University Hospitals Leuven, Belgium W. Coosemans, H. Decaluwé, Ph.
More informationPerioperative outcomes and lymph node assessment after induction therapy in patients with clinical N1 or N2 non-small cell lung cancer
Original Article Perioperative outcomes and lymph node assessment after induction therapy in patients with clinical N1 or N2 non-small cell lung cancer Jessica Glover 1, Frank O. Velez-Cubian 2, Kavian
More informationSegmentectomy for selected ct1n0m0 non small cell lung cancer: A prospective study at a single institute
Segmentectomy for selected ct1n0m0 non small cell lung cancer: A prospective study at a single institute Hiroaki Nomori, PhD, a Takeshi Mori, PhD, b Koei Ikeda, PhD, b Kentaro Yoshimoto, PhD, b Kenichi
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationExpert Round Table with Drs. Anne Tsao and Alex Farivar Part 1: Elderly Man with Indolent Bronchioloalveolar Carcinoma
Expert Round Table with Drs. Anne Tsao and Alex Farivar Part 1: Elderly Man with Indolent Bronchioloalveolar Carcinoma February 2010 I d like to welcome everyone, thanks for coming out to our lunch with
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationThe surgeon: new surgical aproaches
The surgeon: new surgical aproaches Paul Van Schil, MD Department of Thoracic and Vascular Surgery Antwerp University, Belgium no disclosures, no conflict of interest Malignant pleural mesothelioma: clinical,
More informationCASE REPORT. Introduction. Case series reports. J Thorac Dis 2012;4(S1): DOI: /j.issn s003
CASE REPORT Lost in time pulmonary metastases of renal cell carcinoma: complete surgical resection of metachronous metastases, 18 and 15 years after nephrectomy Kosmas Tsakiridis 1, Aikaterini N Visouli
More informationRobotic lobectomy: revolution or evolution?
Editorial Robotic lobectomy: revolution or evolution? Jules Lin Section of Thoracic Surgery, Department of Surgery, University of Michigan Medical Center, Ann Arbor, Michigan, USA Correspondence to: Jules
More information